Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC’s Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislative effort on settlements kicks into high gear with Senate markup and a new bill that would rescind generic exclusivity in some cases.

You may also be interested in...



The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills

The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009

The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills

The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009

Will FTC Challenge Product Switching In Obama Administration?

Lawyers are wary that the Federal Trade Commission may take a more aggressive stance toward pharmaceutical industry practices in the Obama administration

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel